Neuland Laboratories Ltd Q2 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/by1p20jdmt2k9j1kjme9iug0.pdf

Key Takeaways


Portfolio Transformation & Margin Story

Saharsh Davuluri: "we must remain cautious about how business mix, raw material prices or even Forex could negatively impact these margins in the future"

Prime Segment Headwinds

Saharsh Davuluri: "for us it remains a little bit of a concern because we are not very clear in terms of how and when we will recover."

Unit III Ramp-Up & Operating Leverage


Pipeline: Peptides, Deuterated Molecules & NCEs

Sajeev E. Medikonda: "from a commercial perspective this is a long-term bet both for us as well as our customers."

Investment Cycle & Cost Base

Saharsh Davuluri: "I would not shy away from admitting the details of the challenge, however, I think that is an area that we are also investing a lot of time and resources on."

Competitive Landscape & Strategy

Sucheth Davuluri: "...I think it is going to be the European API companies and the Indian API companies that are going to become the formidable supply base for most of the pharmaceutical markets across the world, so I think we are seeing it as an opportunity, our investments reflect that and our investments of the future will also reflect the same."

Guidance & Commitments

CommitmentSpecificsTimeline
Gross margin trajectoryPortfolio mix shift to continue driving higher gross marginsOngoing
Unit III breakevenExpected to be in a good positionBy end of this year
CMS commercializationAt least 2 to 3 molecules to get commercializedNext year or two
Other expenses run-rate~Rs. 63 cr level to continue on an ongoing basisOngoing
Tirzepatide development quantitiesSmall development quantities expected to go outNext 12 to 18 months
Q3 business mixExpected to be similar to Q2Q3 FY23

Key Metrics

MetricQ2 FY23
Total income (H1 FY23)₹515.6 cr, up 11.8% YoY
Gross margin56.2%, vs 53.4% in Q1 FY23 and 49.2% in Q2 FY22
EBITDA (H1 FY23)₹98.4 cr, up 39.1% YoY from ₹70.7 cr in H1 FY22
EBITDA margin (H1 FY23)19.1%, vs 15.3% in H1 FY22
Profit after tax₹38.3 cr, vs ₹20.3 cr in Q2 FY22
EPS₹29.9 per share
Specialty segment revenue~₹96 cr, highest ever
CMS segment revenue~₹97 cr, highest ever, growth of over 40% YoY
Prime segment revenue share30% of total revenues
Other expenses~₹63 cr, up from ₹55-56 cr run rate in prior 4 quarters
Cash and cash equivalents₹5.3 cr on balance sheet at end of period
CMS pipeline: preclinical assets added3 or 4 added in Q2
CMS pipeline: Phase-1 assets added1 or 2 added in Q2
NCE pipeline: total projects~87 odd projects across close to 30 to as many as 50 customers